Shanghai RAAS Blood Products Co Ltd
SZSE:002252
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.2
8.13
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Shanghai RAAS Blood Products Co Ltd
Shanghai RAAS Blood Products Co Ltd
Cash from Financing Activities
Shanghai RAAS Blood Products Co Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Cash from Financing Activities
-¥499.3m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Cash from Financing Activities
¥2.6B
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Cash from Financing Activities
¥2.1B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash from Financing Activities
-¥893.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash from Financing Activities
-¥2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-39%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cash from Financing Activities
-¥1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
|
Shanghai RAAS Blood Products Co Ltd
Glance View
Shanghai RAAS Blood Products Co., Ltd. is a key player in China's biopharmaceutical landscape, specializing in the production and supply of human blood products and diagnostic reagents. Founded in 1992, the company has grown to become one of the largest blood product manufacturers in the country, serving the increasing demand for high-quality and safe blood-derived therapies. The company’s extensive portfolio includes a range of products such as human albumin, immunoglobulins, and coagulants, which are essential for treating various medical conditions, from trauma care to chronic diseases. With a strong commitment to innovation and quality, RAAS has established robust research and development capabilities, ensuring that it stays at the forefront of advancements in blood product technologies. For investors, Shanghai RAAS represents a compelling opportunity in the rapidly expanding Chinese healthcare market. The company operates in a highly regulated environment, giving it a competitive edge through rigorous quality control and adherence to international standards. Furthermore, as China’s aging population grows and healthcare spending increases, the demand for reliable blood products is expected to rise significantly. RAAS has strategically positioned itself to capture this market growth, supported by a diversified customer base that includes hospitals and medical institutions. With its commitment to sustainability, innovation, and shareholder value, investing in Shanghai RAAS not only aligns with a growing industry but also offers the potential for solid returns as the company continues to expand its footprint in both domestic and international markets.
See Also
What is Shanghai RAAS Blood Products Co Ltd's Cash from Financing Activities?
Cash from Financing Activities
-499.3m
CNY
Based on the financial report for Sep 30, 2024, Shanghai RAAS Blood Products Co Ltd's Cash from Financing Activities amounts to -499.3m CNY.
What is Shanghai RAAS Blood Products Co Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-27%
Over the last year, the Cash from Financing Activities growth was 54%. The average annual Cash from Financing Activities growth rates for Shanghai RAAS Blood Products Co Ltd have been 3% over the past three years , -27% over the past five years .
You don't have any saved screeners yet
